2003
Company Outlines Progress Toward Drug Eluting Stent Milestones; Third Quarter and Full-Year 2003 Financial Guidance Affirmed Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in...
Additional Equity Investment Strengthens Guidant''s Commitment to the Development of Future Technologies for Heart Surgery Menlo Park, Calif. - Guidant Corporation (NYSE: GDT), a world leader in...
Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease, will host a mid-quarter conference call to provide an update on the...
Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease, today announced that the company''s board of directors declared a third...
Latest Addition to Pacemaker Portfolio Offers Improved Therapy Options While Maintaining Size and Longevity Brussels, Belgium and St. Paul, Minn. - Guidant Corporation (NYSE: GDT), a world leader...
Calls on Conference to Seize Historic Opportunity to Improve Quality and Expand Access Through Greater Choice, Competition and Innovation Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a...
World''s Smallest Dual Chamber System Offers Enhanced Therapies to Patients at Risk of Sudden Cardiac Death Indianapolis, Ind. and St. Paul, Minn. - Guidant Corporation (NYSE: GDT), a world leader...
Worldwide implantable cardioverter defibrillator revenues of $377 million, up 50 percent; Worldwide stent revenue of $224 million, down 2 percent; Favorable product mix generates 75.4 percent...
Next-Generation Stent Design and Excellent Clinical Results Offer Expanded Treatment Options for Patients Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of...
European Trial Demonstrates Low Restenosis Rate in Stenting of Small Vessels Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease,...